

Checkpoint Inhibitors for Treating Cancer-North America Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/C7D1EB32624EN.html

Date: January 2018 Pages: 132 Price: US\$ 3,480.00 (Single User License) ID: C7D1EB32624EN

Abstracts

Report Summary

Checkpoint Inhibitors for Treating Cancer-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Checkpoint Inhibitors for Treating Cancer industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Checkpoint Inhibitors for Treating Cancer 2013-2017, and development forecast 2018-2023

Main market players of Checkpoint Inhibitors for Treating Cancer in North America, with company and product introduction, position in the Checkpoint Inhibitors for Treating Cancer market

Market status and development trend of Checkpoint Inhibitors for Treating Cancer by types and applications

Cost and profit status of Checkpoint Inhibitors for Treating Cancer, and marketing status Market growth drivers and challenges

The report segments the North America Checkpoint Inhibitors for Treating Cancer market as:

North America Checkpoint Inhibitors for Treating Cancer Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):



United States

Canada Mexico

North America Checkpoint Inhibitors for Treating Cancer Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

PD-1 inhibitors PD-L1 inhibitors CTLA-4 inhibitors

North America Checkpoint Inhibitors for Treating Cancer Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Melanoma treatment Bladder cancer treatment Other

North America Checkpoint Inhibitors for Treating Cancer Market: Players Segment Analysis (Company and Product introduction, Checkpoint Inhibitors for Treating Cancer Sales Volume, Revenue, Price and Gross Margin):

Bristol-Myers Squibb(BMS) Merck Roche

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF CHECKPOINT INHIBITORS FOR TREATING CANCER

- 1.1 Definition of Checkpoint Inhibitors for Treating Cancer in This Report
- 1.2 Commercial Types of Checkpoint Inhibitors for Treating Cancer
- 1.2.1 PD-1 inhibitors
- 1.2.2 PD-L1 inhibitors
- 1.2.3 CTLA-4 inhibitors
- 1.3 Downstream Application of Checkpoint Inhibitors for Treating Cancer
 - 1.3.1 Melanoma treatment
 - 1.3.2 Bladder cancer treatment
 - 1.3.3 Other
- 1.4 Development History of Checkpoint Inhibitors for Treating Cancer
- 1.5 Market Status and Trend of Checkpoint Inhibitors for Treating Cancer 2013-2023

1.5.1 North America Checkpoint Inhibitors for Treating Cancer Market Status and Trend 2013-2023

1.5.2 Regional Checkpoint Inhibitors for Treating Cancer Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Checkpoint Inhibitors for Treating Cancer in North America 2013-2017

2.2 Consumption Market of Checkpoint Inhibitors for Treating Cancer in North America by Regions

2.2.1 Consumption Volume of Checkpoint Inhibitors for Treating Cancer in North America by Regions

2.2.2 Revenue of Checkpoint Inhibitors for Treating Cancer in North America by Regions

2.3 Market Analysis of Checkpoint Inhibitors for Treating Cancer in North America by Regions

2.3.1 Market Analysis of Checkpoint Inhibitors for Treating Cancer in United States 2013-2017

2.3.2 Market Analysis of Checkpoint Inhibitors for Treating Cancer in Canada 2013-2017

2.3.3 Market Analysis of Checkpoint Inhibitors for Treating Cancer in Mexico 2013-2017

2.4 Market Development Forecast of Checkpoint Inhibitors for Treating Cancer in North



America 2018-2023

2.4.1 Market Development Forecast of Checkpoint Inhibitors for Treating Cancer in North America 2018-2023

2.4.2 Market Development Forecast of Checkpoint Inhibitors for Treating Cancer by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole North America Market Status by Types

3.1.1 Consumption Volume of Checkpoint Inhibitors for Treating Cancer in North America by Types

3.1.2 Revenue of Checkpoint Inhibitors for Treating Cancer in North America by Types3.2 North America Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in United States
- 3.2.2 Market Status by Types in Canada
- 3.2.3 Market Status by Types in Mexico

3.3 Market Forecast of Checkpoint Inhibitors for Treating Cancer in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Checkpoint Inhibitors for Treating Cancer in North America by Downstream Industry

4.2 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in Major Countries

4.2.1 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in United States

4.2.2 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in Canada

4.2.3 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in Mexico

4.3 Market Forecast of Checkpoint Inhibitors for Treating Cancer in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER

5.1 North America Economy Situation and Trend Overview



5.2 Checkpoint Inhibitors for Treating Cancer Downstream Industry Situation and Trend Overview

CHAPTER 6 CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

6.1 Sales Volume of Checkpoint Inhibitors for Treating Cancer in North America by Major Players

6.2 Revenue of Checkpoint Inhibitors for Treating Cancer in North America by Major Players

6.3 Basic Information of Checkpoint Inhibitors for Treating Cancer by Major Players

6.3.1 Headquarters Location and Established Time of Checkpoint Inhibitors for Treating Cancer Major Players

6.3.2 Employees and Revenue Level of Checkpoint Inhibitors for Treating Cancer Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 CHECKPOINT INHIBITORS FOR TREATING CANCER MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Bristol-Myers Squibb(BMS)

7.1.1 Company profile

7.1.2 Representative Checkpoint Inhibitors for Treating Cancer Product

7.1.3 Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb(BMS)

7.2 Merck

7.2.1 Company profile

7.2.2 Representative Checkpoint Inhibitors for Treating Cancer Product

7.2.3 Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of Merck

7.3 Roche

7.3.1 Company profile

7.3.2 Representative Checkpoint Inhibitors for Treating Cancer Product

7.3.3 Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of Roche



CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER

- 8.1 Industry Chain of Checkpoint Inhibitors for Treating Cancer
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER

- 9.1 Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer
- 9.2 Raw Materials Cost Analysis of Checkpoint Inhibitors for Treating Cancer
- 9.3 Labor Cost Analysis of Checkpoint Inhibitors for Treating Cancer
- 9.4 Manufacturing Expenses Analysis of Checkpoint Inhibitors for Treating Cancer

CHAPTER 10 MARKETING STATUS ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources



+44 20 8123 2220 info@marketpublishers.com

12.3 Reference



I would like to order

Product name: Checkpoint Inhibitors for Treating Cancer-North America Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/C7D1EB32624EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/C7D1EB32624EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Checkpoint Inhibitors for Treating Cancer-North America Market Status and Trend Report 2013-2023